TICKERNOMICS Sign up
Last Update: 2024-12-27 15:25:26
Autolus Therapeutics plc ( AUTL ) https://www.autolus.com
2.30USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United Kingdom
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-65.31%
AUTL
SPY
32.66%
-55.60%
AUTL
SPY
108.59%
-83.10%
AUTL
SPY
302.52%
AUTL
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
611.99
7.16
1.26
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-2.26
45.12
1.28
-21.29
0.00
-0.03
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-583.98
-18.78
-559.56
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
12.1584
-58.04
-60.28
2.13
Other Earnings and Cash Flow Stats:
Autolus Therapeutics plc ( AUTL ) Net Income TTM ($MM) is -270.23
Autolus Therapeutics plc ( AUTL ) Operating Income TTM ($MM) is -206.45
Autolus Therapeutics plc ( AUTL ) Owners' Earnings Annual ($MM) is 0.00
Autolus Therapeutics plc ( AUTL ) Current Price to Owners' Earnings ratio is 0.00
Autolus Therapeutics plc ( AUTL ) EBITDA TTM ($MM) is -199.03
Autolus Therapeutics plc ( AUTL ) EBITDA Margin is -559.56%
Capital Allocation:
Autolus Therapeutics plc ( AUTL ) has paid 0.00 dividends per share and bought back -92.100488 million shares in the past 12 months
Autolus Therapeutics plc ( AUTL ) has reduced its debt by 0.229 million USD in the last 12 months
Capital Structure:
Autolus Therapeutics plc ( AUTL ) Interest-bearing Debt ($MM) as of last quarter is 52
Autolus Therapeutics plc ( AUTL ) Annual Working Capital Investments ($MM) are -22
Autolus Therapeutics plc ( AUTL ) Book Value ($MM) as of last quarter is 476
Autolus Therapeutics plc ( AUTL ) Debt/Capital as of last quarter is 10%
Other Balance Sheet Stats:
Autolus Therapeutics plc ( AUTL ) has 657 million in cash on hand as of last quarter
Autolus Therapeutics plc ( AUTL ) has 52 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Autolus Therapeutics plc ( AUTL ) has 266 common shares outstanding as of last quarter
Autolus Therapeutics plc ( AUTL ) has 0 million USD of preferred stock value
Academic Scores:
Autolus Therapeutics plc ( AUTL ) Altman Z-Score is -0.68 as of last quarter
Autolus Therapeutics plc ( AUTL ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
Autolus Therapeutics plc ( AUTL ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Autolus Therapeutics plc ( AUTL ) for the amount of $ on
18.09% of Autolus Therapeutics plc ( AUTL ) is held by insiders, and 77.47% is held by institutions
Autolus Therapeutics plc ( AUTL ) went public on 2018-06-22
Other Autolus Therapeutics plc ( AUTL ) financial metrics:
FCF:-205.61
Unlevered Free Cash Flow:0.00
EPS:-1.23
Operating Margin:-583.98
Gross Profit Margin:-18.78
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-68.85
Beta:2.13
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Autolus Therapeutics plc ( AUTL ) :
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.